Top

Cancer Chemotherapy and Pharmacology

Published in:

01-08-2017 | Original Article

Differential effects of thiopurine methyltransferase (TPMT) and multidrug resistance-associated protein gene 4 (MRP4) on mercaptopurine toxicity

Authors: Chengcheng Liu, Laura J. Janke, Jun J. Yang, William E. Evans, John D. Schuetz, Mary V. Relling

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2017

Abstract

Purpose

Mercaptopurine plays a pivotal role in treatment of acute lymphoblastic leukemia (ALL) and autoimmune diseases, and inter-individual variability in mercaptopurine tolerance can influence treatment outcome. Thiopurine methyltransferase (TPMT) and multi-drug resistant Protein 4 (MRP4) have both been associated with mercaptopurine toxicity in clinical studies, but their relative contributions remain unclear.

Methods

We studied the metabolism of and tolerance to mercaptopurine in murine knockout models of Tpmt, Mrp4, and both genes simultaneously.

Results

Upon mercaptopurine treatment, Tpmt ^−/− Mrp4 ^−/− mice had the highest concentration of bone marrow thioguanine nucleotides (8.5 pmol/5 × 10⁶ cells, P = 7.8 × 10⁻⁴ compared with 2.7 pmol/5 × 10⁶ cells in wild-types), followed by those with Mrp4 or Tpmt deficiency alone (6.1 and 4.3 pmol/5 × 10⁶ cells, respectively). Mrp4-deficient mice accumulated higher concentrations of methylmercaptopurine metabolites compared with wild-type (76.5 vs. 23.2 pmol/5 × 10⁶ cells, P = 0.027). Mice exposed to a clinically relevant mercaptopurine dosing regimen displayed differences in toxicity and survival among the genotypes. The double knock-out of both genes experienced greater toxicity and shorter survival compared to the single knockout of either Tpmt (P = 1.7 × 10⁻⁶) or Mrp4 (P = 7.4 × 10⁻¹⁰).

Conclusions

We showed that both Tpmt and Mrp4 influence mercaptopurine disposition and toxicity.

Available only for authorised users

Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH, Evans WE (1999) Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 91:2001–2008CrossRefPubMed

McLeod HL, Coulthard S, Thomas AE, Pritchard SC, King DJ, Richards SM, Eden OB, Hall AG, Gibson BE (1999) Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. Br J Haematol 105(3):696–700CrossRefPubMed

Lennard L, Welch J, Lilleyman JS (1996) Mercaptopurine in childhood leukaemia: the effects of dose escalation on thioguanine nucleotide metabolites. Br J Clin Pharmacol 42(4):525–527CrossRefPubMedPubMedCentral

Bhatia S, Landier W, Hageman L, Chen Y, Kim H, Sun CL, Kornegay N, Evans WE, Angiolillo AL, Bostrom B, Casillas J, Lew G, Maloney KW, Mascarenhas L, Ritchey AK, Termuhlen AM, Carroll WL, Wong FL, Relling MV (2015) Systemic exposure to thiopurines and risk of relapse in children with acute lymphoblastic leukemia: a children’s oncology group study. JAMA oncology 1(3):287–295. doi:10.1001/jamaoncol.2015.0245 CrossRefPubMedPubMedCentral

Relling MV, Hancock ML, Boyett JM, Pui CH, Evans WE (1999) Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 93:2817–2823PubMed

Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM (1991) Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr 119:985–989CrossRefPubMed

Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM (1990) Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336(8709):225–229CrossRefPubMed

McLeod HL, Krynetski EY, Relling MV, Evans WE (2000) Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 14(4):567–572CrossRefPubMed

Hartford C, Vasquez E, Schwab M, Edick MJ, Rehg JE, Grosveld G, Pui CH, Evans WE, Relling MV (2007) Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics. Cancer Res 67(10):4965–4972CrossRefPubMed

10.

Liu C, Yang W, Pei D, Cheng C, Smith C, Landier W, Hageman L, Chen Y, Yang JJ, Crews KR, Kornegay N, Karol SE, Wong FL, Jeha S, Sandlund JT, Ribeiro RR, Rubnitz JE, Metzger ML, Pui CH, Evans WE, Bhatia S, Relling MV (2016) A genome-wide approach validates that thiopurine methyltransferase activity is a monogenic pharmacogenomic trait. Clin Pharmacol Ther. doi:10.1002/cpt.463

11.

Stocco G, Yang W, Crews KR, Thierfelder WE, Decorti G, Londero M, Franca R, Rabusin M, Valsecchi MG, Pei D, Cheng C, Paugh SW, Ramsey LB, Diouf B, McCorkle JR, Jones TS, Pui CH, Relling MV, Evans WE (2012) PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Hum Mol Genet 21(21):4793–4804. doi:10.1093/hmg/dds302 CrossRefPubMedPubMedCentral

12.

Scheuermann TH, Keeler C, Hodsdon ME (2004) Consequences of binding an S-adenosylmethionine analogue on the structure and dynamics of the thiopurine methyltransferase protein backbone. Biochemistry 43(38):12198–12209. doi:10.1021/bi0492556 CrossRefPubMed

13.

Fessing MY, Krynetski EY, Zambetti GP, Evans WE (1998) Functional characterization of the human thiopurine S- methyltransferase (TPMT) gene promoter. Eur J Biochem 256(3):510–517CrossRefPubMed

14.

Yang JJ, Landier W, Yang W, Liu C, Hageman L, Cheng C, Pei D, Chen Y, Crews KR, Kornegay N, Wong FL, Evans WE, Pui CH, Bhatia S, Relling MV (2015) Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol Off J Am Soc Clin Oncol 33(11):1235–1242. doi:10.1200/JCO.2014.59.4671 CrossRef

15.

Wielinga PR, Reid G, Challa EE, van der Heijden I, van Deemter L, de Haas M, Mol C, Kuil AJ, Groeneveld E, Schuetz JD, Brouwer C, De Abreu RA, Wijnholds J, Beijnen JH, Borst P (2002) Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. Mol Pharmacol 62(6):1321–1331CrossRefPubMed

16.

Schuetz JD, Connelly MD, Sun D, Paibir SG, Flynn PM, Srinivas RV, Kumar A, Fridland A (1999) MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 5(9):1048–1051CrossRefPubMed

17.

Chen ZS, Lee K, Kruh GD (2001) Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem 276(36):33747–33754. doi:10.1074/jbc.M104833200 CrossRefPubMed

18.

Peng XX, Shi Z, Damaraju VL, Huang XC, Kruh GD, Wu HC, Zhou Y, Tiwari A, Fu L, Cass CE, Chen ZS (2008) Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine. Leukemia Res 32(5):799–809. doi:10.1016/j.leukres.2007.09.015 CrossRef

19.

Krishnamurthy P, Schwab M, Takenaka K, Nachagari D, Morgan J, Leslie M, Du W, Boyd K, Cheok M, Nakauchi H, Marzolini C, Kim RB, Poonkuzhali B, Schuetz E, Evans W, Relling M, Schuetz JD (2008) Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res 68(13):4983–4989CrossRefPubMedPubMedCentral

20.

Takenaka K, Morgan JA, Scheffer GL, Adachi M, Stewart CF, Sun D, Leggas M, Ejendal KF, Hrycyna CA, Schuetz JD (2007) Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution. Cancer Res 67(14):6965–6972. doi:10.1158/0008-5472.CAN-06-4720 CrossRefPubMed

21.

Tanaka Y, Manabe A, Fukushima H, Suzuki R, Nakadate H, Kondoh K, Nakamura K, Koh K, Fukushima T, Tsuchida M, Koike K, Kiyokawa N, Noguchi E, Sumazaki R, Komiyama T (2015) Multidrug resistance protein 4 (MRP4) polymorphisms impact the 6-mercaptopurine dose tolerance during maintenance therapy in Japanese childhood acute lymphoblastic leukemia. Pharm J 15(4):380–384. doi:10.1038/tpj.2014.74

22.

Ban H, Andoh A, Imaeda H, Kobori A, Bamba S, Tsujikawa T, Sasaki M, Saito Y, Fujiyama Y (2010) The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. J Gastroenterol. doi:10.1007/s00535-010-0248-y

23.

Leggas M, Adachi M, Scheffer GL, Sun D, Wielinga P, Du G, Mercer KE, Zhuang Y, Panetta JC, Johnston B, Scheper RJ, Stewart CF, Schuetz JD (2004) Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol 24(17):7612–7621. doi:10.1128/MCB.24.17.7612-7621.2004 CrossRefPubMedPubMedCentral

24.

Dervieux T, Chu YQ, Su E, Pui CH, Evans WE, Relling MV (2002) HPLC determination of thiopurine nucleosides and nucleotides in vivo in lymphoblast following mercaptopurine. Clin Chem 48:161–168

25.

Su Y, Hon YY, Chu Y, Van de Poll ME, Relling MV (1999) Assay of 6-mercaptopurine and its metabolites in patient plasma by high-performance liquid chromatography with diode-array detection. J ChromatographyB, Biomed Sci Appl 732(2):459–468CrossRef

26.

Pui CH, Evans WE (2006) Treatment of acute lymphoblastic leukemia. N Engl J Med 354(2):166–178CrossRefPubMed

27.

Evans WE, Hon YY, Bomgaars L, Coutre S, Holdsworth M, Janco R, Kalwinsky D, Keller F, Khatib Z, Margolin J, Murray J, Quinn J, Ravindranath Y, Ritchey K, Roberts W, Rogers ZR, Schiff D, Steuber C, Tucci F, Kornegay N, Krynetski EY, Relling MV (2001) Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol Off J Am Soc Clin Oncol 19(8):2293–2301CrossRef

28.

Furmanski BD, Hu S, Fujita K, Li L, Gibson AA, Janke LJ, Williams RT, Schuetz JD, Sparreboom A, Baker SD (2013) Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib. Clin Cancer Res Off J Am Assoc Cancer Res 19(16):4359–4370. doi:10.1158/1078-0432.CCR-13-0980 CrossRef

29.

Stolk JN, Boerbooms AM, De Abreu RA, de Koning DG, van Beusekom HJ, Muller WH, van de Putte LB (1998) Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum 41(10):1858–1866CrossRefPubMed

Title: Differential effects of thiopurine methyltransferase (TPMT) and multidrug resistance-associated protein gene 4 (MRP4) on mercaptopurine toxicity
Authors: Chengcheng Liu
Laura J. Janke
Jun J. Yang
William E. Evans
John D. Schuetz
Mary V. Relling
Publication date: 01-08-2017
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 2/2017
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-017-3361-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2017

Does “OPTINAB” strategy (“stop-and-go”) work in treatment of advanced pancreatic cancer (APC) with nab-paclitaxel–gemcitabine?

Chemotherapy-induced gastrointestinal toxicity is associated with changes in serum and urine metabolome and fecal microbiota in male Sprague–Dawley rats

Assessment of cabozantinib treatment on QT interval in a phase 3 study in medullary thyroid cancer: evaluation of indirect QT effects mediated through treatment-induced changes in serum electrolytes

Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring

Potential for a novel manganese porphyrin compound as adjuvant canine lymphoma therapy

Intracellular vorinostat accumulation and its relationship to histone deacetylase activity in soft tissue sarcoma patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer